Vince & Associates Clinical Research
announced it has been awarded a contract with the
National Institute on Drug Abuse
, part of the
National Institutes of Health (NIH)
, to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medication in humans.
This award is a five year contract with a ceiling value of $9,695,476 beginning September 2012. Vince and Associates will conduct clinical pharmacology studies to support the development of new medications for the treatment of substance abuse disorders.
“Our organization will research investigational medications to include new chemical entities, new biological products such as monoclonal antibodies, enzymes and vaccines as well as already approved drug products,” said
Dr. Brad Vince
, president and medical director of Vince & Associates Clinical Research. “Our organization is excited to work on clinical studies with NIDA that may benefit those struggling with substance abuse disorders.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.